[DOI] [PMC free article] [PubMed] [Google Scholar] Sandstrom PA, Buttke TM
Supporting that remodeling process with targeted peptides creates conditions for better outcomes across multiple measures: skin quality, recovery from exercise, joint health, and metabolic adaptation
External resources for researchers PubChem BPC-157 (CID 9941957) FDA G-SRS BPC-157 (Bepecin) Open-access background: tendon-cell study (preclinical) Related research peptides Disclaimer Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation Supplied to another party for human investigational use
It can be used in a variety of applications, including: Beverages : Allulose sweetens drinks like coffee, tea, and soft drinks without adding carbs
17(5): 592604 Li W, Neugebauer V
A study from the Dutch EB registry found an overall EB incidence of 41.3 per million live births and 22.4 per million population.[129] Similarly, a German study found an EB incidence of 45.1 per million live births.[130] However, a study from England and Wales found a much higher EB incidence of 67.8 per million population.[131] In the most extreme cases, EB can result in the congenital absence of the skin.[132] Dystrophic EB and junctional EB are associated with an increased risk of skin cancer, particularly SCC.[133] While the type of EB can be difficult to determine clinically, next-generation sequencing can define the EB subtype in up to 90% of cases.[134] Diagnosis of EB may be accomplished by immunofluorescence or electron microscopy.[135] The types of EB, pathogenic variants involved, and phenotypic characteristics are detailed in the following review.[136] For more information, see the EB simplex section
